Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular protection for all individuals at high risk: evidence-based best practice.
Bakris G, Böhm M, Dagenais G, Diener HC, Fujita T, Gorelick P, Kjeldsen SE, Laakso M, Mancia G, Pitt B, Sharma A, Sleight P, Teo K, Unger T, Weber M, Williams B, Zannad F. Bakris G, et al. Among authors: dagenais g. Clin Res Cardiol. 2008 Oct;97(10):713-25. doi: 10.1007/s00392-008-0713-2. Epub 2008 Aug 23. Clin Res Cardiol. 2008. PMID: 18726243 Review.
Effect of long-term therapy with ramipril in high-risk women.
Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, Bosch J, Suhan P, Micks M, Probstfield J, Bernstein V, Yusuf S; HOPE Investigators. Heart Outcomes Prevention Evaluation. Lonn E, et al. Among authors: dagenais g. J Am Coll Cardiol. 2002 Aug 21;40(4):693-702. doi: 10.1016/s0735-1097(02)02035-1. J Am Coll Cardiol. 2002. PMID: 12204499 Free article. Clinical Trial.
Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients.
Lonn E, Mathew J, Pogue J, Johnstone D, Danisa K, Bosch J, Baird M, Dagenais G, Sleight P, Yusuf S; Heart Outcomes Prevention Evaluation Study Investigators. Lonn E, et al. Among authors: dagenais g. Eur J Cardiovasc Prev Rehabil. 2003 Dec;10(6):420-8. doi: 10.1097/01.hjr.0000106836.97722.cf. Eur J Cardiovasc Prev Rehabil. 2003. PMID: 14671464 Clinical Trial.
Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. Among authors: dagenais g. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Free article. Clinical Trial.
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Böhm M, et al. Circulation. 2010 Mar 30;121(12):1439-46. doi: 10.1161/CIRCULATIONAHA.109.864199. Epub 2010 Mar 15. Circulation. 2010. PMID: 20231536 Clinical Trial.
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
Verdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda N, Karatzas N, Keltai M, Mancia G, Sleight P, Teo K, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators. Verdecchia P, et al. Among authors: dagenais g. J Hypertens. 2012 May;30(5):1004-14. doi: 10.1097/HJH.0b013e3283522a51. J Hypertens. 2012. PMID: 22495138 Clinical Trial.
342 results